Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 11:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2185–2208 of 8,272 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Age Clear all

Conditions: Age-Related Macular Degeneration, Eye Diseases
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 55 Years to 85 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Body Weight Changes
Interventions: Videos, Action Plans, Discussion Boards, Health behavior tracking; Behavioral
Lead sponsor: University of Nebraska; Other
Eligibility: 40 Years to 64 Years · Female only
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Auburn, Nebraska

Conditions: Eating Disorders
Interventions: Not listed
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 16 Years to 45 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Age Related Macular Degeneration
Interventions: Subretinally injected RetinoStat; Drug
Lead sponsor: Oxford BioMedica; Industry
Eligibility: 50 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 3
States / cities: Iowa City, Iowa • Baltimore, Maryland • Portland, Oregon

Conditions: Age-related Wet Macular Degeneration
Interventions: CG-P5 peptide, Placebo, Aflibercept Injection [Eylea]; Drug
Lead sponsor: Caregen Co. Ltd.; Industry
Eligibility: 50 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 7
States / cities: Manchester, Connecticut • Deerfield Beach, Florida • Augusta, Georgia + 4 more

Conditions: Coagulation in Liver Transplantation
Interventions: Not listed
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Bipolar Disorder
Interventions: lamictal; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 46
States / cities: Dothan, Alabama • Scottsdale, Arizona • San Diego, California + 39 more

Conditions: Surgical Site Infection, Antibiotic Prophylaxis
Interventions: Antibiotics; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Memory Loss
Interventions: Cocoa Flavanol; Dietary Supplement
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 50 Years to 75 Years
Enrollment: 211 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Depression
Interventions: 28 days treatment with Mifepristone.; Drug
Lead sponsor: Stanford University; Other
Eligibility: 50 Years to 70 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Stanford, California

Conditions: Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplasia, Chronic Myeloid Leukemia, Histiocytosis
Interventions: Chemotherapy and antibodies, Miltenyi Biotec CliniMACS, Allogeneic stem cell transplantation; Drug · Device · Procedure
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 24 Months
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2016
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Congestive Heart Failure
Interventions: carvedilol, placebo; Drug
Lead sponsor: Shaddy, Robert, M.D.; Individual
Eligibility: 1 Day to 17 Years
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 21
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 16 more

Conditions: Obesity
Interventions: Not listed
Lead sponsor: Columbia University; Other
Eligibility: Up to 80 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2030
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Conditions: Atopic Dermatitis
Interventions: Upadacitinib, Dupilumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 699 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 31
States / cities: Little Rock, Arkansas • Palo Alto, California • Sacramento, California + 27 more

Conditions: Autism, Cerebral Palsy
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 3 Months to 5 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Neovascular Age-related Macular Degeneration
Interventions: LUBT010 (proposed ranibizumab biosimilar), Lucentis (ranibizumab); Drug
Lead sponsor: Lupin Ltd.; Industry
Eligibility: 50 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 6
States / cities: Beverly Hills, California • Delray Beach, Florida • Hagerstown, Maryland + 3 more

Conditions: Congenital Adrenal Hyperplasia
Interventions: Chronocort®, Standard Care; Drug
Lead sponsor: Neurocrine UK Limited; Industry
Eligibility: 16 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Morehead City, North Carolina

Conditions: Osteosarcoma Metastatic, Ewing's Sarcoma Metastatic
Interventions: Chemotherapy (gemcitabine & docetaxel) plus BIO-11006; Drug
Lead sponsor: Nicklaus Children's Hospital f/k/a Miami Children's Hospital; Other
Eligibility: 5 Years to 21 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Teen Pregnancy
Interventions: DREAMS Curriculum; Other
Lead sponsor: Winter Rose Services, LLC; Other
Eligibility: 13 Years to 19 Years
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11, Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1, Acute Promyelocytic Leukemia With PML-RARA, FLT3 Gene Mutation, Therapy-Related Acute Myeloid Leukemia
Interventions: Biopsy, Bone Marrow Aspiration, Cytarabine, Daunorubicin Hydrochloride, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration, Sorafenib Tosylate; Procedure · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 60 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2021
U.S. locations: 43
States / cities: Lewes, Delaware • Newark, Delaware • Orlando, Florida + 35 more

Conditions: Diabetic Retinopathy
Interventions: blood draw; Biological
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 21 Years to 98 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Epidermolysis Bullosa Dystrophica, Recessive
Interventions: FCX-007; Genetic
Lead sponsor: Castle Creek Biosciences, LLC.; Industry
Eligibility: 7 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 2
States / cities: Stanford, California • Aurora, Colorado

Conditions: Influenza
Interventions: Vero cell derived, trivalent, seasonal influenza vaccine, Licensed egg-derived, trivalent seasonal influenza vaccine; Biological
Lead sponsor: Alachua Government Services, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 3,208 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 30
States / cities: Mobile, Alabama • Tucson, Arizona • Sacramento, California + 25 more

Conditions: Age-Related Macular Degeneration, Geographic Atrophy
Interventions: Not listed
Lead sponsor: Alcon Research; Industry
Eligibility: 55 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Blood and Saliva Sample Collection for AREDS 2

Weight Maintenance Through Physical Activity and Social Support in Rural Middle-Aged Women

Determining the Response to Sipping Beverages Without Swallowing in People With Eating Disorders

Phase I Dose Escalation Safety Study of RetinoStat in Advanced Age-Related Macular Degeneration (AMD)

Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration

Rotational Thromboelastometry (ROTEM) TRUE-NATEM Reference Value Validation in Liver Transplantation

Lamictal as Add-on Treatment for Bipolar I Disorder in Pediatric Patients

The Role of Guideline-adherent Perioperative Antibiotic Administration and the Risk of Surgical Site Infections After Non-cardiac Surgery.

Dietary Flavanols and Dentate Gyrus Function

Effects of Mifepristone on Biomarkers of Metabolic Function and Neuropsychological Performance Among Middle-Aged and Older Individuals

HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies

Safety and Efficacy Study of Carvedilol to Treat Children With Congestive Heart Failure

Study to Investigate Genetic Causes of Severe Early Childhood Onset Obesity.

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

Near-infrared Spectroscopy and Electroencephalography to Assess Cortical Activation During Motor Tasks in Infants and Toddlers With and Without Cerebral Palsy

Study to Compare Efficacy, Safety, and Immunogenicity of LUBT010 (Proposed Ranibizumab Biosimilar) and Lucentis® in Patients With Neovascular AMD

Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy

BIO-11006 for Osteosarcoma and Ewing's Sarcoma Lung Metastases

Evaluation of Curriculum for Teen Pregnancy Prevention: Decisions, Responsibility, Empowerment, Accountability, Motivations & Success

Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia

Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)

A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older

The Natural History of Geographic Atrophy Progression (GAP) Study